Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 58

1.

The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.

Băjenaru O, Ene A, Popescu BO, Szász JA, Sabău M, Mureşan DF, Perju-Dumbrava L, Popescu CD, Constantinescu A, Buraga I, Simu M.

J Neural Transm (Vienna). 2015 Dec 23. [Epub ahead of print]

PMID:
26699635
2.

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A.

Stroke. 2016 Jan;47(1):151-9. doi: 10.1161/STROKEAHA.115.009416. Epub 2015 Nov 12.

3.

Increased connectivity between sensorimotor and attentional areas in Parkinson's disease.

Onu M, Badea L, Roceanu A, Tivarus M, Bajenaru O.

Neuroradiology. 2015 Sep;57(9):957-68. doi: 10.1007/s00234-015-1556-y. Epub 2015 Jul 15.

PMID:
26174425
4.

Chronic migraine - new treatment options.

Roceanu A, Antochi F, Bajenaru O.

Maedica (Buchar). 2014 Dec;9(4):401-4. Review.

5.

Endocarditis and stroke.

Grecu N, Tiu C, Terecoasa E, Bajenaru O.

Maedica (Buchar). 2014 Dec;9(4):375-81.

6.

Evolution of internal carotid artery occlusion in non-traumatic carotid dissection.

Rusu O, Vasile M, Bajenaru O, Antochi F.

Maedica (Buchar). 2014 Jun;9(2):194-7.

7.

Assessment of Venous Thromboembolism Prophylaxis in Neurological Patients with Restricted Mobility - VTE-NEURO Study.

Bajenaru O, Antochi F, Balasa R, Buraga I, Patrichi S, Simu M, Szabolcs S, Tiu C, Zaharia C; VTE-NEURO study group.

Maedica (Buchar). 2014 Mar;9(1):6-14.

8.

Effects and tolerability of betahistine in patients with vestibular vertigo: results from the Romanian contingent of the OSVaLD study.

Băjenaru O, Roceanu AM, Albu S, Zainea V, Pascu A, Georgescu MG, Cozma S, Mărceanu L, Mureşanu DF.

Int J Gen Med. 2014 Dec 4;7:531-8. doi: 10.2147/IJGM.S71015. eCollection 2014.

9.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
10.

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, Correia de Sá J, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y.

J Neurol. 2015 Jan;262(1):248. doi: 10.1007/s00415-014-7565-7. No abstract available.

11.

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y.

J Neurol. 2014 Nov;261(11):2101-11. doi: 10.1007/s00415-014-7446-0. Epub 2014 Aug 14. Erratum in: J Neurol. 2015 Jan;262(1):248.

12.

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.

Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R; Study 018 Investigators.

Mov Disord. 2014 Sep;29(10):1273-80. doi: 10.1002/mds.25961. Epub 2014 Jul 10.

13.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators.

Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.

PMID:
24794721
14.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators.

Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19.

PMID:
24656609
15.

Neurotoxicity of immunosuppressive therapies in organ transplantation.

Anghel D, Tanasescu R, Campeanu A, Lupescu I, Podda G, Bajenaru O.

Maedica (Buchar). 2013 Jun;8(2):170-5. Review.

16.

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R; Study 016 Investigators.

Mov Disord. 2014 Feb;29(2):229-37. doi: 10.1002/mds.25751. Epub 2013 Dec 9.

17.

Label free sensing platform for amyloid fibrils effect on living cells.

Gheorghiu M, David S, Polonschii C, Olaru A, Gaspar S, Bajenaru O, Popescu BO, Gheorghiu E.

Biosens Bioelectron. 2014 Feb 15;52:89-97. doi: 10.1016/j.bios.2013.08.028. Epub 2013 Aug 26.

PMID:
24035851
18.

Growth hormone response to clonidine administration for evaluation of autonomic dysfunction in multiple sclerosis patients.

Petrescu S, Trifanescu R, Ionescu P, Vanghelie GD, Tanasescu R, Moldovan M, Munjev N, Bajenaru O, Panea C.

Maedica (Buchar). 2013 Mar;8(1):11-6.

19.

How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kobys T, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Nehrych T, Moskovko S, Panayiotou P, Jazbec SŠ, Sokolova L, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Voloshyná N, Havrdová E.

Front Neurol. 2013 May 1;4:10. doi: 10.3389/fneur.2013.00010. eCollection 2013.

20.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk